Immediate Impact
3 standout
Citing Papers
Notch signaling pathway in cancer: from mechanistic insights to targeted therapies
2024 Standout
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
2024 Standout
Works of N Herold being referenced
Pathogenic germline variants in SMARCA4 and further cancer predisposition genes in early onset ovarian cancer
2023
Non-small cell neuroendocrine carcinoma of the ovary in a BRCA2-germline mutation carrier: A case report and brief review of the literature
2018
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| N Herold | 8 | 9 | 2 | 11 | 10 | 4 | 27 | |
| Mitul Shah | 5 | 19 | 1 | 12 | 4 | 2 | 31 | |
| Ben Challis | 6 | 8 | 8 | 10 | 15 | 4 | 34 | |
| Stephanie Nesci | 21 | 4 | 1 | 9 | 3 | 3 | 31 | |
| Marianna C. Stern | 6 | 13 | 15 | 13 | 3 | 2 | 36 | |
| Miriam Mints | 7 | 6 | 6 | 13 | 3 | 4 | 31 | |
| Aya Sasaki-Oku | 9 | 18 | 5 | 4 | 3 | 3 | 33 | |
| Diana Dimitrova | 9 | 11 | 3 | 5 | 4 | 5 | 27 | |
| Kathi Adamson | 1 | 7 | 4 | 19 | 10 | 2 | 30 | |
| Mohamed Adil | 5 | 13 | 1 | 10 | 8 | 4 | 36 | |
| Dylan McNally | 4 | 16 | 6 | 3 | 3 | 37 |
All Works
Login with ORCID to disown or claim papers
Loading papers...